News

Net profit of RPG Life Sciences rose 17.00% to Rs 30.76 crore in the quarter ended June 2026 as against Rs 26.29 crore during the previous quarter ended June 2025. Sales rose 15.85% to Rs 195.69 crore in the quarter ended June 2026 as against Rs 168.92 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales195.69168.92 16 OPM %22.1221.00 - PBDT47.3640.57 17 PBT41.4635.43 17 NP30.7626.29 17 Powered by Capital Market - Live News

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 28 July 2026.

RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naproxen and Esomeprazole combination for the first time in India by strengthening the existing business relationship with Archerchem. Naprosyn ES is a combination of Naproxen and Esomeprazole, designed to deliver effective anti-inflammatory solution along with gastro protection. The combination has been co-developed by Archerchem Healthcare along with its development partner. RPG LS will exclusively market and distribute Naprosyn ES across the country and Archerchem as the exclusive supplier. The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, especially among elderly and gastro-sensitive populations.  

RPG Life Sciences announced that the Annual General Meeting(AGM) of the company will be held on 23 July 2026.

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 24 per equity Share (i.e. 300%) , subject to the approval of the shareholders.